<DOC>
	<DOCNO>NCT00226005</DOCNO>
	<brief_summary>The purpose research study find experimental drug call PTK787/ZK222584 might effective advanced metastatic pancreatic cancer . In order tumor grow spread part body , need grow blood supply . Tumor cell show produce substance stimulate abnormal growth new blood vessel allow tumor grow . In adult , blood vessel cell normally divide rapidly . It think PTK787/ZK222584 may interfere growth new blood vessel . A drug interfere growth new blood vessel might stop tumor growth , possibly shrink tumor keep receive nutrient oxygen supply blood vessel . Since normal blood vessel cell divide rarely , might possible stop tumor growth without harm normal tissue .</brief_summary>
	<brief_title>PTK787 Patients With Advanced Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>This open-label , phase II multi-center therapeutic trial investigate efficacy tolerability PTK787/ZK222584 patient metastatic advanced pancreatic cancer fail first line gemcitabine-based therapy . The primary objective study evaluate 6-month survival rate , time progression , tolerability regimen pancreatic cancer patient treat PTK787/ZK222584 second-line therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Age &gt; 18 Zubrod performance status 0 2 Histological cytological diagnosis pancreatic adenocarcinoma Measurable evaluable disease determine per RECIST criterion Life expectancy &gt; 12 week Written inform consent Patients must fail progressed prior gemcitabinebased therapy advance metastatic disease . Islet cell neuroendocrine carcinoma pancreas . History presence central nervous system disease . Patients history another primary malignancy &lt; 5 year Prior chemo therapy &lt; 21 day prior registration . Prior biologic immunotherapy &lt; 14 day prior registration Prior full field radiotherapy &lt; 28 day limited field radiotherapy &lt; 14 day prior registration . Major surgery &lt; 28 day prior registration . Patients receive investigational drug &lt; 28 day prior registration . Prior therapy antiVEGF agent . Pleural effusion ascites cause respiratory compromise . Female patient pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pancreas</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>Phase II</keyword>
	<keyword>growth factor</keyword>
	<keyword>VEGF</keyword>
	<keyword>angiogenesis</keyword>
</DOC>